Business Wire

Teva Announces tomy’s Award Winner at Oncology Satellite Symposium During the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy

Del

Teva Pharmaceuticals Europe BV, (NYSE and TASE: TEVA) announced the winner of the tomy’s (Teva’s Orphan hematological Malignancies award for Young hematologists) at the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy last week. During the event entitled, ‘Next-Generation APL Leaders: Teva’s Award for Young Hematologists’ Dr. Salamero was awarded a tomy’s trophy, as well as a bursary to attend the 2017 American Society of Hematology (ASH) Annual Meeting, taking place in the USA in December.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171005005748/en/

Dr. Olga Salamero presenting her research during the Next-Generation APL Leaders Teva’s Award for Yo ...

Dr. Olga Salamero presenting her research during the Next-Generation APL Leaders Teva’s Award for Young Hematologists in Rome, Italy (Photo: Business Wire)

Dr. Salamero is currently a hematologist at the Vall d’Hebron University Hospital, Barcelona, Spain and presented research entitled Very elderly acute promyelocytic leukemia: a multicentric experience. The study selected patients aged ≥ 75 years old with APL who had reported to PETHEMA registry (Spanish Hematology Treatment Programme) over the last nineteen years. Epidemiologic characteristics and disease features in the very elderly APL population were analysed and the percentage of patients treated according to investigators criteria described. The research found that patients treated with all-trans retinoic acid (ATRA) plus anthracycline-based regimen showed better outcomes than patients who received other strategies, such as ATRA alone, chemotherapy alone or best supportive care.

Speaking after the awards ceremony, Dr. Salamero said, “Winning the tomy’s - it’s been a pleasure. I feel proud, not because of my work but the work of the PETHEMA group. I would recommend attending the APL Symposium as not only is it very interesting, but it facilitates a lot and keeps you in touch with your peers.”

The tomy’s are an educational award programme for young hematologists, sponsored by Teva Oncology. The awards are open to young hematologists, or young physicians training to become hematologists aged 40 years or younger. The entrants are challenged to illustrate the latest scientific advancements in the management of orphan hematological malignancies by presenting a case study or case series demonstrating their excellence in education and presentation skills. The independent jury for the 2017 tomy’s was comprised of experts in orphan hematological malignancies and includes Pierre Fenaux, France; Richard Schlenk, Germany; Francesco Lo-Coco, Italy; Bob Löwenberg, Netherlands; Nigel Russell, UK and Miguel Sanz, Spain.

“It’s estimated that between 1,500 – 2,000 people in Europe are diagnosed with APL each year. Even though APL is the most lethal type of acute leukemia, it’s highly curable and more research into this disorder is urgently needed. The tomy’s programme reflects Teva’s commitment to encouraging new and innovative research aimed at improving patient outcomes in orphan hematological malignancies,” said Paul Harmon, Head of Teva’s Oncology Care and Transplant Europe.

“APL can cause a number of symptoms including uncontrollable bleeding and can kill within hours or days if left untreated. As it’s so rare, APL can be difficult to recognise and diagnose. We’re excited about this programme, and we believe it will stimulate new exciting research, with the ultimate ambition of saving lives,” commented Prof. Lo-Coco, tomy jury member.

The full list of finalists as well as more information on the jury can be accessed via: https://www.thinkapl.com/jury/

The tomy’s awards ceremony in Rome follows the inaugural tomy’s awards, announced at the Teva Oncology Satellite Symposium at the Acute Leukemias XVI International Symposium, which took place in Munich, Germany, in February 2017.

For more information on the Tomy’s awards or for queries regarding abstract submissions or notifications, please contact: support@oncotomys.com.

-ENDS-

About Teva

Teva is among the top 15 global pharmaceutical companies globally, delivering high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 60 markets every day. Teva produces a leading innovative treatment for multiple sclerosis and has late-stage development programs for a range of disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions. With its European headquarters in Amsterdam, the Netherlands, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a broad range of products in nearly every therapeutic area. Teva draws on its specialty and generics capabilities to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.

Contact information

Teva
Fiona Cohen
+31 6 2008 2545
or
Jayson Otke
+31 6 8201 5407

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Manchester United Shoots for Success with a “Digital Experience Platform” Powered by HCL16.8.2018 19:02Pressemelding

Manchester United (NYSE:MANU) has today announced a major milestone on its digital transformation journey with HCL Technologies, with the successful launch of the Manchester United Official app powered by HCL’s digital experience platform. The launch is part of the ongoing digital transformation of the club to provide a real-time, engaging, personalized, and unified experience to Manchester United’s 659 million global followers, which supports the club’s strategy to become a Digital Sports Enterprise. At the heart of this transformation is the digital platform developed by HCL, providing the club with a single view of fans across web and app touchpoints, offering fans a one-stop shop for everything Manchester United. Manchester United’s Group Managing Director Richard Arnold comments: “This app will allow our 659 million Manchester United followers to easily connect to the club they love, wherever they are in the world. Fans will now have the opportunity to follow all Manchester United

4K 4Charity Fun Run Announces Open Registration for IBC201816.8.2018 17:41Pressemelding

AWS Elemental, an Amazon Web Services (AWS) company, today announced that the fifth annual 4K 4Charity Fun Run at IBC Show will take place at 7:00 a.m. local time on Saturday, Sept. 15 at Amstelpark in Amsterdam. Registration is open at https://4k4charity.com/ibc. Among the non-profits supported by the 4K 4Charity Fun Run at IBC Show is Amsterdam-based StichtingNewTechKids, which provides computer science education for girls, minorities, and economically challenged youth in the Netherlands. The organization supports a computer science teacher training program for primary school teachers with proceeds from 4K 4Charity. Also supported is Iridescent, a global education non-profit that empowers underrepresented young people to become innovators and leaders through engineering and technology. Through their two programs, Curiosity Machine AI Family Challenge and Technovation, Iridescent introduces underserved communities to new technologies and empowers and equips them to apply those technol

2018 D.I.C.E. Cannes Announced Round 3 Speakers16.8.2018 14:01Pressemelding

The Academy of Interactive Arts & Sciences’ D.I.C.E. Cannes event will take place 9-11 September 2018 at the Hotel Barrière Le Majestic Cannes in France. Leading video game executives will participate in the premier networking opportunities, listen to key speakers address the conference theme - Trailblazers - to tackle some of the industry’s biggest ideas and trends. Newly announced speakers include: Craig Duncan, Studio Head at Rare – Duncan will share his studio’s experience and learnings with “A Rare Voyage of Adventure.” Duncan will provide insight into Rare’s bold new IP Sea of Thieves, a game that has inspired friendships and players creating stories together. David Hubert, Animation and Cinematic Director at Eidos Montreal – In Hubert’s talk he will discuss how cinematics are redefining AAA story-driven games and how they will continue to shape the medium to push the envelope throughout the production process. Adam Orth – In a session titled “Digging for Fire: Virtual Reality 20

GN Hearing and Google Announce Partnership to Bring Direct Mobile Streaming from Android Devices to Hearing Aids16.8.2018 13:00Pressemelding

GN Hearing and Google have today announced a new technology partnership that will make GN Hearing the first manufacturer to enable a full spectrum of direct audio streaming from Android devices to hearing aids. The expectations are that direct streaming will become available to hearing aid users of the recently launched hearing aids ReSound LiNX Quattro™ and Beltone Amaze™ in a future Android release. “According to the World Health Organization, around 466 million people worldwide have disabling hearing loss. This number is expected to increase to 900 million people by the year 2050. Google is working with GN Hearing to create a new open specification for hearing aid streaming support on future versions of Android devices,” states Seang Chau, Vice President of Engineering at Google. Users will be able to connect and monitor their hearing aids, so they can get the full advantages of their Android devices without using an intermediate device for streaming to their hearing aids. This will

Zurich Expands Global Use of Guidewire InsurancePlatform with Selection of Guidewire Cyence Risk Analytics16.8.2018 12:55Pressemelding

Guidewire Software, Inc. (NYSE: GWRE), the provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced that Zurich Insurance Group (Zurich) has selected Guidewire Cyence™ Risk Analytics (Cyence) to leverage the cyber risk knowledge and insights the solution provides to help the company prospect, underwrite, and price risks. Zurich will roll out Cyence globally with an emphasis on enhanced analytics and intelligence for risk selection. Unprecedented technological advances of the 21st century have shifted the nature of risk across the P&C insurance industry. Ever-evolving cyber risks present unique challenges including limited availability of traditional actuarial data needed to model these risks. Cyence combines economic modeling, cybersecurity, machine learning and Internet scale data collection to help risk takers assess the financial impact of cyber risk. “After conducting a thorough search, we found that the capabilities of Guidewire Cyence Risk

Scientist.com Named One of America’s Ten Fastest-Growing Private Companies by Inc. Magazine16.8.2018 12:06Pressemelding

Scientist.com, the world’s leading marketplace for outsourced scientific services, today announced that it ranked no. 9 on Inc. magazine’s 2018 list of the 5,000 fastest-growing, privately owned companies in America. Scientist.com ranked no. 2 nationally in the Health category and no. 2 in the state of California. The San Diego-based company builds private marketplaces that connect life science research organizations with a global network of over 2,600 contract research organizations (CROs) and providers of scientific services. “Our mission is to empower and connect scientists worldwide and make it possible to cure all human diseases by 2050,” stated Kevin Lustig, Scientist.com’s CEO and Founder. “On Scientist.com, a single, highly trained scientist can run an entire drug discovery program from concept to clinic from his or her laptop without ever physically entering a laboratory.” The pharmaceutical industry spends about $150B a year on medical research and produces about 25 new medic